Multi-Gene Mutations Detection Kit

 Multi-Gene Mutations Detection Kit
Detection of 118 hotspot mutations/fusions in EGFR/ KRAS/ BRAF/ NRAS/ HER2/ PIK3CA/ ALK/ ROS1/RET genes.
Patients with NSCLC often harbor driver mutations in multiple oncogenes, including EGFR, ALK, ROS1, BRAF, HER2, RET, etc. The presence of gene alterations can impact the selection of and the response to targeted therapies. Testing of lung cancer for multi-gene mutations is important for identification of potentially efficacious targeted therapies. Therefore, identifying mutations in oncogenes and tailoring therapy accordingly are widely accepted in clinical cancer management. Faster detection of driver mutations enables quicker initiation of proper therapy.
AmoyDx Multi-Gene Mutations Detection Kit is a real-time PCR assay for detection of 118 hotspot mutations/fusions in 9 driver genes (EGFR, KRAS, BRAF, NRAS, HER2, PIK3CA, ALK, ROS1 and RET genes) in NSCLC at a time from a single tissue specimen.

Technological Principles
The assay contains mRNA-based fusion detection and DNA-based mutation detection.
The RNA gene fusion detection system uses specific primers and fluorescent probes which are designed for both side genes of the fusion, combining a one-step RT-PCR procedure to detect ALK, ROS1 and RET gene fusions based on tumor message RNA. The protocol comprises reverse transcription of target RNA and reference gene RNA to generate complementary DNA (cDNA) and simultaneous PCR amplification of resulting cDNA.
The DNA gene mutation detection system uses ADx-ARMS technology, which comprises specific primers and fluorescent probes to detect mutations in EGFR, KRAS, BRAF, NRAS, HER2, and PIK3CA genes. During the amplification, the target mutant DNA is matched with the bases at 3’ end of the primer, and amplified efficiently, then the mutant amplicon is detected by fluorescent-labeled probes. While the wild-type DNA cannot be matched with specific primers, there is no amplification occurs.